OTCPK:USNU

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

U.S. NeuroSurgical Holdings

Executive Summary

U.S. NeuroSurgical Holdings, Inc., through its subsidiaries, owns and operates stereotactic radiosurgery centers that utilize gamma knife technology. More Details


Snowflake Analysis

Flawless balance sheet and undervalued.

Share Price & News

How has U.S. NeuroSurgical Holdings's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: USNU's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

0%

USNU

-2.3%

US Healthcare

-0.8%

US Market


1 Year Return

9.2%

USNU

21.0%

US Healthcare

13.8%

US Market

Return vs Industry: USNU underperformed the US Healthcare industry which returned 21% over the past year.

Return vs Market: USNU underperformed the US Market which returned 13.8% over the past year.


Shareholder returns

USNUIndustryMarket
7 Day0%-2.3%-0.8%
30 Day-3.7%-4.9%-5.7%
90 Day28.1%0.4%8.6%
1 Year9.2%9.2%22.6%21.0%16.4%13.8%
3 Year-36.6%-36.6%23.9%18.5%36.9%27.8%
5 Year18.2%18.2%50.0%39.4%85.0%64.2%

Price Volatility Vs. Market

How volatile is U.S. NeuroSurgical Holdings's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is U.S. NeuroSurgical Holdings undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: USNU ($0.26) is trading below our estimate of fair value ($2.76)

Significantly Below Fair Value: USNU is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: USNU is good value based on its PE Ratio (8.6x) compared to the US Healthcare industry average (22.2x).

PE vs Market: USNU is good value based on its PE Ratio (8.6x) compared to the US market (17.6x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate USNU's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: USNU is good value based on its PB Ratio (0.6x) compared to the US Healthcare industry average (2.8x).


Next Steps

Future Growth

How is U.S. NeuroSurgical Holdings forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

13.9%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as U.S. NeuroSurgical Holdings has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

  • Examine whether U.S. NeuroSurgical Holdings is trading at an attractive price based on how much it is expected to earn in the future, and relative to its industry peers and the wider market.
  • While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on theOTC Markets Website. If you are looking for more of a qualitative research into the company, you can access U.S. NeuroSurgical Holdings's filings and announcementshere.
  • Explore growth companies in the Healthcare industry.

Past Performance

How has U.S. NeuroSurgical Holdings performed over the past 5 years?

-37.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: USNU has high quality earnings.

Growing Profit Margin: USNU became profitable in the past.


Past Earnings Growth Analysis

Earnings Trend: USNU's earnings have declined by 37.8% per year over the past 5 years.

Accelerating Growth: USNU has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: USNU has become profitable in the last year, making it difficult to compare its past year earnings growth to the Healthcare industry (31.1%).


Return on Equity

High ROE: USNU's Return on Equity (7%) is considered low.


Next Steps

Financial Health

How is U.S. NeuroSurgical Holdings's financial position?


Financial Position Analysis

Short Term Liabilities: USNU's short term assets ($3.3M) exceed its short term liabilities ($1.6M).

Long Term Liabilities: USNU's short term assets ($3.3M) exceed its long term liabilities ($98.0K).


Debt to Equity History and Analysis

Debt Level: USNU is debt free.

Reducing Debt: USNU had no debt 5 years ago.

Debt Coverage: USNU has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: USNU has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Next Steps

Dividend

What is U.S. NeuroSurgical Holdings's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate USNU's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate USNU's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if USNU's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if USNU's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of USNU's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

US$300k

CEO Compensation


CEO

Alan Gold (75 yo)

no data

Tenure

US$300,000

Compensation

Mr. Alan Gold has been the Chairman and President of U.S. NeuroSurgical Holdings, Inc. (formerly known as US Neurosurgical Inc.) since 1996 and serves as the Chief Executive Officer. He served as Principal ...


CEO Compensation Analysis

Compensation vs Market: Alan's total compensation ($USD0.00) is below average for companies of similar size in the US market ($USD604.44K).

Compensation vs Earnings: Alan's compensation has been consistent with company performance over the past year.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

U.S. NeuroSurgical Holdings, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: U.S. NeuroSurgical Holdings, Inc.
  • Ticker: USNU
  • Exchange: OTCPK
  • Founded: 1993
  • Industry: Health Care Facilities
  • Sector: Healthcare
  • Market Cap: US$2.026m
  • Shares outstanding: 7.79m
  • Website: https://www.usneuro.com

Number of Employees


Location

  • U.S. NeuroSurgical Holdings, Inc.
  • 2400 Research Boulevard
  • Suite 325
  • Rockville
  • Maryland
  • 20850
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
USNUOTCPK (Pink Sheets LLC)YesCommon StockUSUSDOct 1999

Biography

U.S. NeuroSurgical Holdings, Inc., through its subsidiaries, owns and operates stereotactic radiosurgery centers that utilize gamma knife technology. The gamma knife is a stereotactic radiosurgical device ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/09/28 05:33
End of Day Share Price2020/09/25 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.